- Home
- FEDU vs CMMB Comparison
FEDU vs CMMB Comparison
Compare FEDU & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- CMMB
- Stock Information
- Founded
- FEDU 2007
- CMMB 2004
- Country
- FEDU China
- CMMB Israel
- Employees
- FEDU N/A
- CMMB N/A
- Industry
- FEDU
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- CMMB Health Care
- Exchange
- FEDU NYSE
- CMMB Nasdaq
- Market Cap
- FEDU 21.6M
- CMMB 23.0M
- IPO Year
- FEDU 2017
- CMMB N/A
- Fundamental
- Price
- FEDU $10.50
- CMMB $1.20
- Analyst Decision
- FEDU
- CMMB Strong Buy
- Analyst Count
- FEDU 0
- CMMB 2
- Target Price
- FEDU N/A
- CMMB $8.50
- AVG Volume (30 Days)
- FEDU 781.0
- CMMB 228.9K
- Earning Date
- FEDU 06-30-2025
- CMMB 08-20-2025
- Dividend Yield
- FEDU 21.71%
- CMMB N/A
- EPS Growth
- FEDU N/A
- CMMB N/A
- EPS
- FEDU 0.12
- CMMB N/A
- Revenue
- FEDU $27,971,139.00
- CMMB N/A
- Revenue This Year
- FEDU N/A
- CMMB N/A
- Revenue Next Year
- FEDU N/A
- CMMB N/A
- P/E Ratio
- FEDU $88.10
- CMMB N/A
- Revenue Growth
- FEDU 141.14
- CMMB N/A
- 52 Week Low
- FEDU $3.69
- CMMB $0.87
- 52 Week High
- FEDU $22.70
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- FEDU 70.43
- CMMB 39.89
- Support Level
- FEDU $9.49
- CMMB $1.10
- Resistance Level
- FEDU $10.19
- CMMB $1.26
- Average True Range (ATR)
- FEDU 0.27
- CMMB 0.08
- MACD
- FEDU -0.02
- CMMB -0.02
- Stochastic Oscillator
- FEDU 100.00
- CMMB 35.71
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.